Ovarian Cancer News and Research

Latest Ovarian Cancer News and Research

Aethlon Medical plans to initiate patient recruitment for cancer immunotherapy study

Aethlon Medical, Inc., the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announced today that it plans to initiate patient recruitment for a cancer immunotherapy study by year end. The pilot study seeks to demonstrate an improved immune function in cancer patients as a result of the Aethlon Hemopurifier removing tumor-secreted exosomes from the circulatory system.

4 May 2010

Phase 2 clinical trial data of voreloxin to be presented at 2010 ASCO Annual Meeting: MicroStockProfit.com

MicroStockProfit.com announces an investment report featuring Sunesis Pharmaceuticals Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

4 May 2010

Interim study results demonstrate anti-tumor activity of CytRx's INNO-206 in myeloma tumor cells

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced interim study results that showed its doxorubicin prodrug INNO-206 demonstrated statistically significant anti-tumor activity in human myeloma tumor cells growing in immune-deficient mice compared to a control group, while exhibiting significantly less toxicity than doxorubicin even though INNO-206 was administered at much higher doses.

3 May 2010

ImmunoCellular Therapeutics seeks FDA orphan drug status for ICT-107 dendritic-cell based vaccine for GBM

ImmunoCellular Therapeutics announced today it has filed an orphan drug application with the U.S. Food and Drug Administration (FDA) for its cancer treatment candidate ICT-107. ICT-107 is a dendritic-cell based cancer vaccine product which targets glioblastoma multiforme (GBM), the most prevalent, aggressive and malignant form of primary brain tumors.

3 May 2010

FDA approves continuation of Phase IIb clinical trial for superficial bladder cancer

Tikcro Technologies Ltd. today announced that BioCancell Therapeutics, Inc., concluded the first 18 patient group treated pursuant to a Phase IIb clinical trial of the drug candidate BC-819 for use in superficial bladder cancer. These patients had not responded to conventional treatment.

3 May 2010

CPMC establishes new Bryan Hemming Cancer Care Center

Being diagnosed with cancer can be devastating for anyone, bringing with it a series of life-changing challenges, both physical and emotional. That's why California Pacific Medical Center is delighted to announce the opening of the Bryan Hemming Cancer Care Center, a one-of-a-kind space offering a wide range of essential support services for patients and their loved ones, all under one roof.

3 May 2010

Women with family history of breast cancer face increase risk of ovarian cancer

Ovarian cancer is the most deadly disease of the female reproductive system, with most cases diagnosed in later stages. Yet while ovarian cancer affects 1 in 70 women in the United States, many women have never discussed the risk with their doctor.

30 Apr 2010

Immunogen reports a net loss of $12.1 million in third quarter 2010

ImmunoGen, Inc., a biotechnology company that develops targeted anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced financial results for the three-month period ended March 31, 2010 - the third quarter of the Company's 2010 fiscal year (3QFY10).

30 Apr 2010

Incorporation of NexACT technology helps reduce dose of Å6 compound for ovarian cancer treatment

NexMed, Inc., a specialty CRO with a pipeline of products based on the NexACT® technology, today announced that results from a pre-clinical study showed significant improvement in the delivery and half life of Å6, a proprietary peptide treatment for ovarian cancer currently in Phase 2 development by Angstrom Pharmaceuticals. Specifically, the incorporation of NexACT® enabled the dose of Å6 to be cut by half, or from twice per day to once per day delivered subcutaneously, while achieving the same level of efficacy in the mouse lung metastasis model.

29 Apr 2010

Study: Curcumin nanoparticles limit toxicity of cancer therapy

Pre-treatment with curcumin, a component of the spice turmeric, makes ovarian cancer cells more vulnerable to chemotherapy and radiotherapy. Researchers writing in BioMed Central's open access Journal of Ovarian Research found that delivering the curcumin via very small (less than 100nm) nanoparticles enhanced the sensitizing effect.

29 Apr 2010

New report on women's largest cancer challenge: lung cancer

Out of the Shadows: Women and Lung Cancer, a groundbreaking report released today by the Mary Horrigan Connors Center for Women's Health at Brigham and Women's Hospital, a teaching affiliate of Harvard Medical School, is a call to action on women's largest cancer challenge: lung cancer.

27 Apr 2010

Waxman Foundation honors molecular biologist Alan Ashworth with the David T. Workman Memorial Award

Molecular biologist Alan Ashworth, Ph.D., FRS, the director of the Breakthrough Breast Cancer Research Centre at the Institute of Cancer Research in London will receive the David T. Workman Memorial Award on May 17. The two-year grant of $50,000 from the Samuel Waxman Cancer Research Foundation will support Dr. Ashworth's work with PARP inhibitors in BRCA-mutated cancers.

23 Apr 2010

Hereditary ovarian cancer patients may develop secondary tumours in liver and spleen

Scientists have taken a major step forward in the understanding of ovarian cancer, which could improve treatment for patients with the condition.

22 Apr 2010

PharmaMar presents new trials with Yondelis, Zalypsis and Irvalec anti-tumor drugs at 101st AACR meeting

PharmaMar, a biopharmaceutical company owned by Grupo Zeltia (ZEL.MC), presented six new trials with marine-based anti-tumor drugs Yondelis(R), Zalypsis(R) and Irvalec(R) at the American Association for Cancer Research's (AACR) 101st Annual Meeting, held in Washington, D.C. from April 17-21.

22 Apr 2010

Manhattan Scientifics' early cancer detection technology offers better results than mammogram test

Manhattan Scientifics, Inc. announced today that its "early cancer detection" technology, developed by Edward R. Flynn, Ph.D. is expected to identify breast cancer three years earlier than the current gold standard mammogram test. Dr. Flynn is a pioneer in the emerging field of nano medicine.

22 Apr 2010

ImmunoCellular Therapeutics, UPENN sign research agreement

ImmunoCellular Therapeutics, Ltd., a biotechnology company that is developing immune based therapies for the treatment of various forms of cancer, announced today that the Company has entered into a sponsored research agreement and an option agreement with The University of Pennsylvania to support process development and manufacturing in a planned Phase II clinical trial of ICT-107, the Company's dendritic-cell based cancer vaccine product candidate for the treatment of glioblastoma multiforme.

22 Apr 2010

Study links mutations in RAD51C gene to breast and ovarian cancer

The discovery 15 years ago that the genes BRCA1 and BRCA2 confer high risks for breast and ovarian cancer was a breakthrough for cancer prediction and therapy, especially for familial cases. Now the research group of Prof. Alfons Meindl (Klinikum rechts der Isar of the Technische Universitaet Muenchen), in collaboration with other groups from Germany, the U.K., and the U.S., can identify another gene that increases susceptibility to breast and ovarian cancer.

22 Apr 2010

Access Pharmaceuticals to present MuGard clinical data at 2010 MASCC conference

ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company specializing in products for cancer and supportive care, announced today that it will present data from the ongoing work involving its lead product, MuGard, and host an oral mucositis symposium at the MASCC conference being held in Vancouver, B.C. on June 24-26, 2010. MuGard is Access Pharma's FDA-approved product for the management of oral mucositis, a debilitating side effect of many anticancer treatments.

22 Apr 2010

Abbott's first-quarter worldwide pharmaceutical sales increases by 12.9%

Abbott today announced financial results for the first quarter ended March 31, 2010.

21 Apr 2010

Tea for Teal event raises $15,000 for TGen ovarian cancer research

The Anne Rita Monahan Foundation recently presented $15,000 for ovarian cancer research to the Translational Genomics Research Institute (TGen).

21 Apr 2010

Ovarian Cancer News and Research

Latest Ovarian Cancer News and Research

Aethlon Medical plans to initiate patient recruitment for cancer immunotherapy study

Phase 2 clinical trial data of voreloxin to be presented at 2010 ASCO Annual Meeting: MicroStockProfit.com

Interim study results demonstrate anti-tumor activity of CytRx's INNO-206 in myeloma tumor cells

ImmunoCellular Therapeutics seeks FDA orphan drug status for ICT-107 dendritic-cell based vaccine for GBM

FDA approves continuation of Phase IIb clinical trial for superficial bladder cancer

CPMC establishes new Bryan Hemming Cancer Care Center

Women with family history of breast cancer face increase risk of ovarian cancer

Immunogen reports a net loss of $12.1 million in third quarter 2010

Incorporation of NexACT technology helps reduce dose of Å6 compound for ovarian cancer treatment

Study: Curcumin nanoparticles limit toxicity of cancer therapy

New report on women's largest cancer challenge: lung cancer

Waxman Foundation honors molecular biologist Alan Ashworth with the David T. Workman Memorial Award

Hereditary ovarian cancer patients may develop secondary tumours in liver and spleen

PharmaMar presents new trials with Yondelis, Zalypsis and Irvalec anti-tumor drugs at 101st AACR meeting

Manhattan Scientifics' early cancer detection technology offers better results than mammogram test

ImmunoCellular Therapeutics, UPENN sign research agreement

Study links mutations in RAD51C gene to breast and ovarian cancer

Access Pharmaceuticals to present MuGard clinical data at 2010 MASCC conference

Abbott's first-quarter worldwide pharmaceutical sales increases by 12.9%

Tea for Teal event raises $15,000 for TGen ovarian cancer research

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Ovarian Cancer News and Research

Latest Ovarian Cancer News and Research

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Newsletters you may be interested in